Thalia Therapeutics

Default features description for sign up page.

Regulatory news

Home

Media

AIM Rule 26

Open Sans

THALIA THERAPEUTICS INVESTOR CENTRE

N4Pharma.pdf

Explore Biotech Innovation with N4 Pharma

Share Magazine shines a spotlight on N4 Pharma (N4P:AIM), revolutionising biotech with advanced delivery systems for nucleic acids in oncology, gene therapy, and vaccines. Our patented mesoporous silica nanoparticles and newly acquired lipid-peptide delivery platform ensure precise, targeted treatment.

We aim to become a leading supplier to major pharma and biotech companies, currently pursuing orphan drug designation and pre-IND approval.

Discover our breakthroughs and engage with us on our interactive investor hub. Submit your questions via the 'Ask a question' button and be part of our journey to transform medicine.

Sign up to the N4 investor hub so you don't miss out on future company news here.

Share Spotlight: Biotech firm N4 Pharma is delivering cutting edge solutions to the UK